Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dutasteride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 known ✓ | P18405 | 19/20 | 1.00 |
| ▸ | SRD5A2 known ✓ | P31213 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | KEAP1 | Q14145 | 1/20 | 1.00 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dutasteride SCHEMBL1832772 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL1285958 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL9975973 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL1108295 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL13495828 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL997007 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL10028296 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL12194984 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL20776136 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| Dutasteride SCHEMBL4775587 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNAABCB11GLRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13005 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107401-A2 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF POLYLACTIC ACID FOR HAIR GROWTH | DURAIRAJ KALPNA KAY (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260115207-A1 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | HEALTH RESEARCH INC (US) | 2026-04-30 | — | — | US | claimed |
| US-12599613-B2 | Composition comprising dutasteride | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2026-04-14 | — | — | US | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-12582651-B2 | Pharmaceutical composition comprising tadalafil or pharmaceutically acceptable salt thereof and dutasteride or pharmaceutically acceptable salt thereof exhibiting novel dissolution rate | DONG KOOK PHARM. CO., LTD. (KR) | 2026-03-24 | — | — | US | claimed |
| US-12582601-B2 | Orodispersible powder composition | BIOPHARMA SYNERGIES, S.L. (ES) | 2026-03-24 | — | — | US | claimed |
| US-20260076981-A1 | HAIR REGROWTH TOPICAL COMPOSITION | SPEIER GARY J (US) | 2026-03-19 | — | — | US | claimed |
| US-20260060913-A1 | BIOACTIVE WALNUT PEPTIDES FOR TREATING HAIR LOSS | L'OREAL (FR) | 2026-03-05 | — | — | US | claimed |
| US-20260060936-A1 | INDOLIUM-BASED STABILIZERS OF HYDROPHOBIC DRUGS | TECHNION RES & DEV FOUNDATION (IL) | 2026-03-05 | — | — | US | claimed |
| EP-4698175-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-02-25 | — | — | EP | claimed |
| EP-1173141-A1 | SHAMPOOS PROVIDING A SUPERIOR COMBINATION OF ANTI-DANDRUFF EFFICACY AND CONDITIONING | The Procter & Gamble Company (US) | 2002-01-23 | — | — | EP | claimed |
| US-20010048942-A1 | Dutasteride to prevent and treat atherosclerosis | WEISMAN KENNETH (US) | 2001-12-06 | — | — | US | claimed |
| US-20010047022-A1 | Treatment or prevention of prostate cancer with a COX-2 selective inhibiting drug | MERCK & CO., INC. | 2001-11-29 | — | — | US | claimed |
| US-20010041713-A1 | Treatment or prevention of prostate cancer with a COX-2 selective inhibiting drug | WALDSTREICHER JOANNE (US) | 2001-11-15 | — | — | US | claimed |
| WO-2001060365-A1 | TREATMENT OR PREVENTION OF PROSTATE CANCER WITH A COX-2 SELECTIVE INHIBITING DRUG | MERCK & CO., INC. (US) | 2001-08-23 | — | — | WO | claimed |
| WO-2001054688-A1 | TREATMENT OR PREVENTION OF PROSTATE CANCER WITH A COX-2 SELECTIVE INHIBITING DRUG | MERCK & CO., INC. (US) | 2001-08-02 | — | — | WO | claimed |
| WO-2000066072-A1 | SHAMPOOS PROVIDING A SUPERIOR COMBINATION OF ANTI-DANDRUFF EFFICACY AND CONDITIONING | THE PROCTER & GAMBLE COMPANY (US) | 2000-11-09 | — | — | WO | claimed |
| WO-1999036030-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DI-HYDROXYTESTOSTERONE DEPENDENT CONDITIONS | DAVITZ, MICHAEL, A. (US) | 1999-07-22 | — | — | WO | claimed |
| EP-0859617-A1 | METHOD OF PREVENTING ANDROGENETIC ALOPECIA WITH 5-ALPHA REDUCTASE INHIBITORS | Merck & Co., Inc. (US) | 1998-08-26 | — | — | EP | claimed |
| WO-1997011702-A1 | METHOD OF PREVENTING ANDROGENETIC ALOPECIA WITH 5-ALPHA REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1997-04-03 | — | — | WO | claimed |